Navigation Links
Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
Date:10/27/2008

September 30, March 31,

2008 2008

Current assets:

Cash and cash equivalents $34,572 $17,219

Short-term investments 34,998 6,991

Trade receivables, net 21,613 20,873

Inventories, net 17,580 18,657

Prepaid expenses 1,093 427

Net deferred tax asset - current 3,204 2,426

Total current assets 113,060 66,593

Long-term investments - 35,463

Property and equipment, net 14,865 14,599

Intangible assets, net 338 375

Other assets 23 5

Net deferred tax asset - non-current 3,771 3,868

Total assets $132,057 $120,903

Current liabilities:

Accounts payable $4,956 $6,421

Accrued payroll and related expenses 4,231 4,277

Other accrued liabilities 2,312 1,369

Deferred revenue 934 807

Warranty reserve 1,617 1,219

Total current liabilities 14,050 14,093

Non-current liabilities:

Deferred rent 217 286

Deferred revenue 1,439 1,146

Warranty reserve 625 729

Total non-current liabilities 2,281 2,161

'/>"/>
SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
2. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
9. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
10. Aware, Inc. Reports Third Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2
... January 28 The Binding Site Limited,("The Binding ... company, today announces the publication of the first,international ... and management of multiple myeloma, a cancer of ... disorders. , The guidelines ...
... an announcement made recently by Astellas Pharma Inc., CV Therapeutics, ... received a letter dated November 13, 2008 from Astellas setting ... at a price of $16.00 per share, subject to due ... deliberation, with the assistance of its financial and legal advisors, ...
... PTS by Albemarle responds to the demand in ... 27 Leading specialty chemical company, Albemarle Corporation, ... company, Zymes LLC, have joined forces to scale-up ... The next generation technology promotes the clear ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... A new GSA Bulletin study uses tree ... Puerco and Chaco Wash in northern New Mexico, USA. ... cedar and willow, investigators were able to precisely date ... then combined this data with aerial imagery, LiDAR, longitudinal ... these arroyos. , Arroyos are deep, oversized channels that ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... ever had trouble sleeping can attest to the difficulties at work ... for ideal health and productivity, but what if five to six ... negatively affected? A team of researchers at Brigham and Women,s ... yourself to be, that lack of sleep can influence the way ...
... People for the Ethical Treatment of Animals (PETA) Foundation ... today alleging that the European Chemicals Agency (ECHA) is ... investigating cases in which animal testing could be avoided ... complaints about maladministration in EU institutions and agencies, and ...
... Mass., July 26, 2012  Aware, Inc. (NASDAQ: AWRE ), ... today reported financial results for its second quarter ended June 30, ... was $5.3 million, a decrease of 10% compared to $5.9 million ... second quarter of 2012 was $369,000 compared to a loss of ...
Cached Biology News:The longer you're awake, the slower you get 2PETA files complaint with European ombudsman over animal testing for REACH 2Aware, Inc. Reports Second Quarter 2012 Financial Results 2Aware, Inc. Reports Second Quarter 2012 Financial Results 3Aware, Inc. Reports Second Quarter 2012 Financial Results 4Aware, Inc. Reports Second Quarter 2012 Financial Results 5Aware, Inc. Reports Second Quarter 2012 Financial Results 6
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
...
... Protein, 1. Based on the methodology ... kit gives essentially colorless backgrounds in ... Protein provides convenient, reproducible and sensitive ... in less than two hours.The visualization ...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Biology Products: